Related Experiment Video

Updated: May 17, 2026

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

Suppression of NF-κB reduces myocardial no-reflow

Min Zeng1, Hongbing Yan, Yi Chen

  • 1Department of Cardiology, Beijing Anzhen Hospital, the Capital Medical University, China.

Plos One
|October 12, 2012
PubMed

Insights

Inhibition of nuclear factor kappa B (NF-κB) reduces myocardial no-reflow after ischemia/reperfusion injury. This approach mitigates inflammation, improving outcomes for acute myocardial infarction patients.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Inflammation Research

Background:

  • The no-reflow phenomenon complicates acute myocardial infarction treatment, limiting reperfusion benefits.
  • Inflammation, particularly via nuclear factor kappa B (NF-κB), is implicated in ischemia/reperfusion (I/R) injury and no-reflow.
  • Targeting NF-κB presents a potential strategy to mitigate myocardial damage.

Purpose of the Study:

  • To investigate the role of NF-κB inhibition in reducing myocardial no-reflow following I/R injury.
  • To assess the impact of NF-κB inhibition on inflammatory markers and neutrophil infiltration in the myocardium.
  • To evaluate the efficacy of pyrrolidine dithiocarbamate (PDTC) as an NF-κB inhibitor in an animal model and cell culture.

Main Methods:

  • Induction of I/R injury in rabbit coronary arteries via ligation and reperfusion.
  • Administration of the NF-κB inhibitor PDTC prior to reperfusion.
  • Measurement of no-reflow area, neutrophil infiltration, and serum levels of TNF-α, ICAM-1, and CXCL16.
  • In vitro study using human umbilical vein endothelial cells (HUVECs) subjected to simulated I/R, with PDTC or p65 siRNA treatment.

Main Results:

  • PDTC treatment significantly reduced neutrophil infiltration and the extent of no-reflow in rabbits.
  • Serum levels of TNF-α, ICAM-1, and CXCL16 were markedly decreased in PDTC-treated rabbits.
  • In HUVECs, PDTC and p65 knockdown suppressed I/R-induced increases in TNF-α, ICAM-1, and CXCL16.

Conclusions:

  • Inhibition of NF-κB signaling effectively reduces myocardial no-reflow and associated inflammation in I/R injury.
  • Targeting NF-κB with agents like PDTC holds therapeutic potential for improving outcomes in acute myocardial infarction.
  • The findings highlight the critical role of the NF-κB pathway in mediating inflammatory responses during cardiac I/R injury.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...